Role of Organic Cation Transporter 3 and Plasma Membrane Monoamine Transporter in the Rewarding Properties and Locomotor Sensitizing Effects of Amphetamine in Male andFemale Mice.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
14 Dec 2021
Historique:
received: 01 11 2021
revised: 03 12 2021
accepted: 03 12 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 12 1 2022
Statut: epublish

Résumé

A lack of effective treatment and sex-based disparities in psychostimulant addiction and overdose warrant further investigation into mechanisms underlying the abuse-related effects of amphetamine-like stimulants. Uptake-2 transporters such as organic cation transporter 3 (OCT3) and plasma membrane monoamine transporter (PMAT), lesser studied potential targets for the actions of stimulant drugs, are known to play a role in monoaminergic neurotransmission. Our goal was to examine the roles of OCT3 and PMAT in mediating amphetamine (1 mg/kg)-induced conditioned place preference (CPP) and sensitization to its locomotor stimulant effects, in males and females, using pharmacological, decynium-22 (D22; 0.1 mg/kg, a blocker of OCT3 and PMAT) and genetic (constitutive OCT3 and PMAT knockout (-/-) mice) approaches. Our results show that OCT3 is necessary for the development of CPP to amphetamine in males, whereas in females, PMAT is necessary for the ability of D22 to prevent the development of CPP to amphetamine. Both OCT3 and PMAT appear to be important for development of sensitization to the locomotor stimulant effect of amphetamine in females, and PMAT in males. Taken together, these findings support an important, sex-dependent role of OCT3 and PMAT in the rewarding and locomotor stimulant effects of amphetamine.

Identifiants

pubmed: 34948221
pii: ijms222413420
doi: 10.3390/ijms222413420
pmc: PMC8708598
pii:
doi:

Substances chimiques

Central Nervous System Stimulants 0
Octamer Transcription Factor-3 0
Pou5f1 protein, mouse 0
Vesicular Monoamine Transport Proteins 0
Amphetamine CK833KGX7E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIDA NIH HHS
ID : R21 DA049044
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA031115
Pays : United States
Organisme : NIH HHS
ID : NIH R21 DA049044
Pays : United States

Références

Neuropsychopharmacology. 2018 Nov;43(12):2408-2417
pubmed: 29773909
CNS Drugs. 2014 Dec;28(12):1115-26
pubmed: 25373627
Handb Exp Pharmacol. 2021;266:1-39
pubmed: 33782773
Handb Exp Pharmacol. 2021;266:253-280
pubmed: 33751232
Physiol Behav. 1986;38(5):663-6
pubmed: 3823180
J Cereb Blood Flow Metab. 2016 Dec;36(12):2122-2133
pubmed: 26661218
Adv Pharmacol. 2014;69:129-76
pubmed: 24484977
Neuron. 2011 Feb 24;69(4):628-49
pubmed: 21338876
Psychopharmacology (Berl). 1992;106(3):330-6
pubmed: 1570378
J Neurochem. 2008 Aug;106(3):1471-82
pubmed: 18513366
Annu Rev Psychol. 2003;54:25-53
pubmed: 12185211
Physiol Behav. 1975 May;14(5):601-8
pubmed: 1135316
Physiol Behav. 1976 Apr;16(4):413-7
pubmed: 959343
MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):349-358
pubmed: 29596405
Eur J Neurosci. 2018 May 24;:
pubmed: 29797618
Drug Alcohol Depend. 2016 Apr 1;161:104-9
pubmed: 26874915
Eur J Pharmacol. 2019 Jan 5;842:351-364
pubmed: 30473490
Lancet. 2012 Jan 7;379(9810):55-70
pubmed: 22225671
Pharmacol Biochem Behav. 1980 Oct;13(4):501-5
pubmed: 7433482
J Chem Neuroanat. 2013 Sep;52:36-43
pubmed: 23694905
J Neurosci. 2000 Feb 1;20(3):1229-39
pubmed: 10648727
Pharmacol Rev. 2020 Jan;72(1):253-319
pubmed: 31852803
Adv Exp Med Biol. 2010;670:80-91
pubmed: 20384220
J Comp Neurol. 2009 Feb 1;512(4):529-55
pubmed: 19025979
Addiction. 1999 Sep;94(9):1413-9
pubmed: 10615725
Pharmacol Biochem Behav. 2000 Mar;65(3):419-23
pubmed: 10683481
MMWR Morb Mortal Wkly Rep. 2019 May 03;68(17):388-395
pubmed: 31048676
Psychopharmacology (Berl). 2004 Mar;172(3):264-70
pubmed: 14600800
Psychopharmacology (Berl). 2000 Dec;153(1):31-43
pubmed: 11255927
Psychopharmacology (Berl). 2016 Jun;233(11):2015-2024
pubmed: 25066361
J Neurochem. 2005 Jun;93(6):1434-43
pubmed: 15935059
Handb Exp Pharmacol. 2021;266:187-197
pubmed: 33987762
Handb Exp Pharmacol. 2021;266:41-80
pubmed: 33963461
J Neurosci. 2006 Oct 25;26(43):11041-51
pubmed: 17065446
Dev Psychobiol. 1980 Mar;13(2):107-10
pubmed: 7358217
Nat Protoc. 2006;1(4):1662-70
pubmed: 17487149
Addiction. 2019 Dec;114(12):2122-2136
pubmed: 31328345
J Neurosci. 2006 Aug 23;26(34):8758-66
pubmed: 16928864
Neuroscience. 2009 Oct 20;163(3):890-7
pubmed: 19580849
Brain Res. 1981 Oct 26;223(1):229-34
pubmed: 7284807
J Biol Chem. 2004 Nov 26;279(48):50042-9
pubmed: 15448143
J Neural Transm (Vienna). 2009 Jun;116(6):689-97
pubmed: 19280114
Trends Pharmacol Sci. 2015 Jan;36(1):41-50
pubmed: 25542076
Neuropharmacology. 2018 Aug;138:267-274
pubmed: 29908241
Biol Sex Differ. 2012 Jun 07;3(1):14
pubmed: 22676718
Drug Alcohol Depend. 2021 Jan 1;218:108384
pubmed: 33158665
Behav Neurosci. 1997 Dec;111(6):1324-34
pubmed: 9438801
Psychopharmacology (Berl). 1992;107(2-3):385-93
pubmed: 1352057
J Pharmacol Exp Ther. 2010 Dec;335(3):743-53
pubmed: 20858707
Handb Exp Pharmacol. 2021;266:199-214
pubmed: 33993413
Mol Cell Biol. 2001 Jul;21(13):4188-96
pubmed: 11390648
Eur J Neurosci. 2020 Dec;52(11):4546-4562
pubmed: 32725894
Curr Top Behav Neurosci. 2010;3:179-95
pubmed: 21161753
Pharmacol Biochem Behav. 1978 Dec;9(6):777-83
pubmed: 570708
Addict Behav. 2004 Jan;29(1):89-106
pubmed: 14667423
Alcohol Clin Exp Res. 2006 Oct;30(10):1644-9
pubmed: 17010131
Neuropharmacology. 2014 Jan;76 Pt B:329-41
pubmed: 23664810
Psychopharmacology (Berl). 2001 May;155(3):278-84
pubmed: 11432690
Prog Neurobiol. 2005 Apr;75(6):406-33
pubmed: 15955613
Neuropharmacology. 2007 Jul;53(1):113-24
pubmed: 17559891
Neuropsychopharmacology. 2019 Jan;44(1):166-183
pubmed: 29946108
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18976-81
pubmed: 19033200
J Neurosci. 2013 Jun 19;33(25):10534-43
pubmed: 23785165
Neurochem Int. 2019 Feb;123:46-49
pubmed: 30055194
J Neurosci. 2013 Jul 17;33(29):11800-10
pubmed: 23864669
Neuropharmacology. 2009;56 Suppl 1:133-8
pubmed: 18662707
Proc Natl Acad Sci U S A. 2004 May 18;101(20):7781-6
pubmed: 15136721
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jun 1;37(2):237-46
pubmed: 22361156
Neuropsychopharmacology. 2017 Feb;42(3):757-765
pubmed: 27604564
Eur J Pharmacol. 2000 Oct 6;406(1):1-13
pubmed: 11011026
Brain Res Dev Brain Res. 2004 Nov 25;153(2):213-23
pubmed: 15527889
Behav Pharmacol. 2006 Nov;17(7):597-604
pubmed: 17021392

Auteurs

Nikki J Clauss (NJ)

Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Wouter Koek (W)

Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Lynette C Daws (LC)

Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH